Voyager Therapeutics Inc Dossier - Source-backed chat

Voyager Therapeutics Inc

VYGRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.21

Intrinsic Value $4.37median of 2 methodsbased on filings through 30 Jun 2026

Market Price $2.68Price as of 30 Sep 2026

Significantly undervaluedIntrinsic value is 63% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+63%)

Data confidence Sign in to view data confidence

Market Cap $165.1M

Enterprise Value $163.9M

Shares Outstanding 60.2M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Voyager Therapeutics is a clinical-stage biotechnology company leveraging its proprietary TRACER™ AAV capsid discovery platform to develop gene therapies for severe neurological diseases. The company's investment thesis is anchored on its robust pipeline targeting tau knockdown in Alzheimer's disease, backed by high-profile pharmaceutical collaborations (including Novartis, Neurocrine Biosciences, and Alexion/AstraZeneca) that provide non-dilutive funding and validate its platform. With a strong cash runway extending into 2028, Voyager is well-positioned to reach critical clinical milestones in the second half of 2026, including first-in-human dosing for its tau-silencing gene therapy VY1706 and key tau PET imaging efficacy data for its anti-tau antibody VY7523.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$14.89

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

VY1706 encounters unexpected safety concerns or clinical holds during its Phase 1 trial, or the VY7523 PET imaging data fails to show meaningful tau knockdown. Additionally, partner-led programs face regulatory delays, and higher-than-expected clinical trial costs accelerate cash burn, forcing a dilutive equity raise before 2028 and damaging investor confidence in the TRACER platform.

Base CaseCentral scenario

Voyager successfully initiates the Phase 1 clinical trial for VY1706 in Alzheimer's disease in H2 2026 following its recent FDA IND clearance. Concurrently, the MAD clinical trial for VY7523 yields positive tau PET imaging efficacy data, validating the company's tau-targeting approach. Partner Neurocrine Biosciences successfully initiates the clinical trial for NBIB-223 in Friedreich's ataxia. The company maintains disciplined expense management, preserving its cash runway into 2028 and attracting further platform collaborations.

Bull CaseUpside scenario

Voyager's proprietary TRACER capsid platform successfully crosses the blood-brain barrier to deliver highly effective gene therapies, validated by upcoming clinical readouts for wholly-owned assets (VY1706 and VY7523) and partnered programs with blue-chip collaborators (Neurocrine and Novartis), unlocking a multi-billion dollar market in neurological diseases.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary TRACER™ AAV capsid discovery platform enables high brain penetration and blood-brain barrier crossing with lower systemic exposure.
Strong validation through active collaborations with industry leaders including Novartis, Neurocrine Biosciences, and Alexion (AstraZeneca Rare Disease).
Robust financial position with $171.7 million in cash, cash equivalents, and marketable securities, providing an operational runway into 2028.
Imminent high-impact clinical catalysts in H2 2026, including first-in-human dosing of VY1706 and tau PET imaging data for VY7523.

Key Investment Risks

High clinical and regulatory risks inherent to gene therapy and central nervous system (CNS) drug development.
Heavy reliance on partners for the clinical advancement and commercialization of key pipeline assets.
Pre-revenue status with ongoing net losses ($27.9 million in Q1 2026) and long-term capital requirements before commercialization.

Thesis Invalidation Triggers

Failure to initiate the Phase 1 trial of VY1706 in H2 2026 or unexpected FDA clinical holds.
Negative or inconclusive tau PET imaging efficacy data from the VY7523 MAD clinical trial.
Termination or significant downscaling of major collaboration agreements by Novartis or Neurocrine Biosciences.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.